Virus News and Research

Latest Virus News and Research

Infection prevention: an interview with Dr. Robert Gorab, Chief Medical Officer, Hoag Orthopedic Institute

HOI has one of the lowest if not the lowest surgical readmission rate in the State of California. Our all-cause readmission rate is 3.3% and our joint replacement readmission was at 1.8% based on published CMS reports we received in September 2013.

12 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

FOXO3 transcription factor may protect against alcohol-induced liver injury

New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis.

11 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

New outbreak of polio in Syria may endanger neighbouring regions, warn experts

Two infectious disease experts have written to The Lancet warning that a new outbreak of polio (due to infection with wild-type polio virus 1, WPV1) in Syria, recently confirmed by WHO, might endanger neighbouring regions, including Europe.

8 Nov 2013

Gladstone-led study sheds light on critical molecular process

One of biology's most fundamental processes is something called transcription. It is just one step of many required to build proteins-and without it life would not exist. However, many aspects of transcription remain shrouded in mystery. But now, scientists at the Gladstone Institutes are shedding light on key aspects of transcription, and in so doing are coming even closer to understanding the importance of this process in the growth and development of cells-as well as what happens when this process goes awry.

8 Nov 2013

University of Adelaide research uses special adult stem cells to treat Hurler's syndrome

University of Adelaide research using special adult stem cells is promising new hope for better treatments for the devastating genetic disease Hurler's syndrome.

7 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Probiotics may help keep bad germs at bay

Microbes are everywhere - thousands of species are in your mouth, and thousands are in a glass of tap water. The ones in your mouth are mostly harmless - as long as you brush and floss so they don't form a biofilm that allows gum disease a path into the blood stream.

4 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Tips for combating fall allergies

Fall allergies and rapidly changing temperatures send many people reaching for pain relievers or other remedies to deal with runny noses and other symptoms associated with sinus and allergy problems.

31 Oct 2013

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

Making fat cells immortal might seem like a bad idea to most people, but for a team of University of Iowa scientists it was the ideal way to study how the interaction between bacteria and fat cells might contribute to diabetes.

31 Oct 2013

EcoHealth Alliance discovers new SARS-like coronavirus in Chinese horseshoe bats

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, announced the discovery of a new SARS-like coronavirus (CoV) in Chinese horseshoe bats.

31 Oct 2013

New insights into human cytomegalovirus may lead to development of therapeutic interventions

New insights into how human cytomegalovirus, the leading cause of birth defects associated with infection spreads from pregnant mother to fetus and from organ to organ in newborns provides translational researchers an exciting new avenue for investigation that may lead to the development of therapeutic interventions.

31 Oct 2013

Study examines link between geographic region and HPV vaccine uptake among young women

Initiation and completion rates for the human papillomavirus vaccine series are significantly lower in the South than any other geographic region, according to a new study from researchers at the University of Texas Medical Branch at Galveston.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a corrective or replacement gene to treat disease.

30 Oct 2013

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all.

29 Oct 2013

Virus News and Research

Latest Virus News and Research

Infection prevention: an interview with Dr. Robert Gorab, Chief Medical Officer, Hoag Orthopedic Institute

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

FOXO3 transcription factor may protect against alcohol-induced liver injury

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

New outbreak of polio in Syria may endanger neighbouring regions, warn experts

Gladstone-led study sheds light on critical molecular process

University of Adelaide research uses special adult stem cells to treat Hurler's syndrome

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Probiotics may help keep bad germs at bay

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Tips for combating fall allergies

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

EcoHealth Alliance discovers new SARS-like coronavirus in Chinese horseshoe bats

New insights into human cytomegalovirus may lead to development of therapeutic interventions

Study examines link between geographic region and HPV vaccine uptake among young women

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Researchers overcome obstacle to using viruses to deliver therapeutic genes

EPFL and UNIL-CHUV scientists create first map of human HIV resistance

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Virus News and Research

Latest Virus News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in